Trial Profile
A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs SL 701 (Primary) ; Poly ICLC
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 31 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 31 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 31 Oct 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.